The compelling NPP survival data and upcoming June 2026 DURIPANC milestones create a binary catalyst for AIM. Traders should watch for the Mid-Year 2026 report and enrollment completion — positive DURIPANC interim data could drive significant upside, while any delay or negative read would be bearish. The $2M market cap amplifies sensitivity to these catalysts.
Price Chart
Executive Summary
AIM ImmunoTech posted a Virtual Investor KOL Connect segment featuring Prof. Dr. Casper H.J. van Eijck discussing Ampligen's data in late-stage pancreatic cancer. The segment highlights positive survival data from the completed Named Patient Program (NPP) and interim data from the ongoing Phase 2 DURIPANC study. A Mid-Year 2026 report with enrollment completion and milestones is expected in June 2026.
Key Facts
- NPP data showed PFS of 12.6 months vs 8.6 months for historical controls (4-month improvement) and OS of 19.7 months vs 12.5 months (7.2-month improvement).
- In NPP patients with NLR <4.5, PFS was 17.7 months vs 8.6 months (9.1-month improvement) and OS was 34.8 months vs 12.5 months (22.3-month improvement).
- In NPP patients with CA 19-9 <1000, PFS was 13.1 months vs 8.6 months (4.5-month improvement) and OS was 24.1 months vs 12.5 months (11.6-month improvement).
- Mid-Year 2026 report, completion of enrollment and milestones for the Phase 2 DURIPANC study expected in June 2026.
- DURIPANC is a Phase 2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) in metastatic pancreatic cancer patients post-FOLFIRINOX.
Financial Impact
No financial data provided; clinical data updates only
Risk Factors
- Clinical-stage biotech with no approved products and no revenue — binary risk on DURIPANC results.
- Phase 2 interim data may not replicate NPP results; historical control comparisons are not randomized.
- Company has a $2M market cap and may face financing risk to complete the Phase 2 trial.
- Forward-looking statements only — no guarantee of regulatory approval or commercial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022891 |
| Exhibit: ex99-1.htm | 0001493152-26-022891 |
| Document: 0001493152-26-022891-index-headers.html | 0001493152-26-022891 |
| Document: 0001493152-26-022891-index.html | 0001493152-26-022891 |
| Document: 0001493152-26-022891.txt | 0001493152-26-022891 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers